세계의 신경 바이오마커 시장 규모, 점유율, 성장 분석, 유형별, 용도별, 최종사용자별, 지역별 시장 규모, 점유율, 성장 분석 - 산업 예측(2024-2031년)

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

The global neurological biomarkers market is poised for significant expansion, driven primarily by the rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, alongside an increasing demand for precise diagnostic tools. The aging global population and lifestyle factors have resulted in a surge of these conditions, fueling the need for effective diagnostics that enable early intervention and enhanced disease management. The shift towards precision medicine and targeted therapies further accelerates the demand for neurological biomarkers, which allow healthcare providers to tailor treatments based on individual genetic and molecular profiles, thereby optimizing outcomes while minimizing adverse effects. However, the market confronts challenges stemming from the intricate nature of neurological diseases, which complicates the identification and validation of reliable biomarkers. Extensive research and clinical trials are necessary to determine the sensitivity, specificity, and predictive value of biomarkers, often leading to time-consuming and costly processes. Additionally, regulatory and ethical challenges related to biomarker development, such as ensuring patient privacy and informed consent, need careful consideration from both researchers and healthcare professionals. The lack of standardization in biomarker assays and data interpretation presents another hurdle, as inconsistencies in laboratory techniques can hinder comparability across studies. Nevertheless, with a robust market trajectory, the US neurological biomarkers sector is expected to witness sustainable growth and promising opportunities in the forthcoming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurological Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurological Biomarkers Market Segmental Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Driver of the Neurological Biomarkers Market

The rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, serves as a critical market driver for the global neurological biomarkers market. With the aging population and lifestyle factors contributing to the surge in these conditions, there is an escalating demand for accurate, early diagnostic tools that can facilitate timely intervention and improve patient outcomes. Neurological biomarkers play a vital role in enhancing disease detection, monitoring progression, and evaluating treatment efficacy. As healthcare providers and researchers increasingly recognize the importance of personalized medicine, the need for innovative biomarkers to support tailored therapeutic approaches further propels market growth in this sector.

Restraints in the Neurological Biomarkers Market

One of the significant market restraints for the neurological biomarkers industry is the extensive and resource-intensive process required for their discovery and validation. This involves conducting comprehensive research and lengthy clinical trials that not only demand substantial financial investment but also extended timelines, which can impede the speed of bringing these innovations to market. Consequently, the high costs associated with the development and validation of biomarkers can limit access to these advanced diagnostic and therapeutic options, making them less affordable for healthcare providers and patients alike. This financial barrier may hinder the widespread adoption of neurological biomarkers in clinical practice, ultimately affecting market growth.

Market Trends of the Neurological Biomarkers Market

The Neurological Biomarkers market is witnessing a significant trend towards the integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies, which are revolutionizing biomarker research and data analysis. This shift enables the automation of data interpretation, thereby streamlining the identification of critical patterns and facilitating accurate predictions of disease outcomes. As a result, the efficiency and precision in the discovery and validation of neurological biomarkers are markedly improved. The increasing adoption of AI and ML not only accelerates research timelines but also enhances the overall reliability of diagnostics, reflecting a transformative movement that is poised to redefine approaches to neurological disorders.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pipeline Analysis
• Penetration and Growth Prospects Analysis
• PESTEL Analysis
• Patent Analysis

Neurological Biomarkers Market, By Type

• Market Overview
• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

Neurological Biomarkers Market, By Application

• Market Overview
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

Neurological Biomarkers Market, By End User

• Market Overview
• Hospital & Hospital Laboratories
• Independent clinical diagnostic centers
• Research Organizations and Others

Neurological Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Quanterix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cisbio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C2N Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunArray
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euroimmun AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments